An operation that targets the nerves connected to the kidney has been found to significantly reduce blood pressure in patients with hypertension, according to the results of a clinical trial led in the UK by Queen Mary University of London and Barts Health NHS Trust, and supported by the National Institute for Health Research (NIHR).
If the findings are confirmed in more extensive clinical trials, the surgery could offer hope to patients with high blood pressure who do not respond to drugs, and are at increased risk of cardiovascular diseases, including stroke and heart attack.
The international clinical trial, carried out from 2017 to 2018 at St Bartholomew’s Hospital in the UK by the NIHRBarts Biomedical Research Centre, tested a one-hour operation called ‘renal denervation’, which uses ultrasound energy to disrupt the nerves between the kidneys and the brain that carry signals for controlling blood pressure.
Significant reduction in blood pressure
146 patients in the United States, France, Germany, the Netherlands, Belgium and the United Kingdom were randomised to receive either renal denervation or a ‘sham procedure’ – the surgical equivalent of a placebo. Patients also remained off blood pressure medications for two months unless specified blood pressure levels were exceeded.
After two months, the renal denervation group experienced an 8.5 mm Hg reduction in blood pressure, which was a 6.3 mm Hg greater reduction compared with the sham group.
More than 66 per cent of subjects treated with renal denervation demonstrated a 5 mm Hg or greater reduction in blood pressure, compared with 33 per cent in the sham group.
No major adverse events were reported in either group, and the blood pressure lowering effect of renal denervation was consistent across sex and ethnicity.
An alternative to lifelong medications
UK Principal Investigator Dr Melvin Lobo from Queen Mary’s William Harvey Research Institute and Barts Health NHS Trust said: “These results leave us clinicians in no doubt that this ultrasound-based therapy works to improve blood pressure control – at least in the short term. Further larger trials will be needed to confirm the efficacy and safety of the technology, but we hope that they could lead to renal denervation therapy being offered as an alternative to lifelong medications for hypertension.”
The study has limitations including the short follow-up time of two months. This was done for safety reasons to minimise the duration of patients being off antihypertensive medications. Longer follow-up of this trial and additional numbers of treated patients will be necessary to provide greater assurance of safety and to exclude rare adverse events.
The Latest on: Hypertension
via Google News
The Latest on: Hypertension
- Sanofi, Church Partner On Diabetes, Hypertension Management on September 18, 2018 at 5:00 pm
In a bid to address the growing incidence of diabetes and hypertension in Nigeria, multinational healthcare company, Sanofi, and the Catholic Archdiocese of Lagos, has entered into an agreement to ... […]
- Secondary Ocular Hypertension and the Risk of Glaucoma Surgery After Dexamethasone Intravitreal Implant in Routine Clinical Practice on September 18, 2018 at 1:36 pm
To determine the rate of ocular hypertension (OHT) after dexamethasone intravitreal implant in routine clinical practice and identify patient characteristics associated with a risk for glaucoma surger... […]
- Study of Over a Million People Reveals New Hypertension Genes on September 17, 2018 at 12:10 pm
After assessing data from over one million patients, a team of scientists at Queen Mary University of London and Imperial College London have found 500 new areas in the human genome that play a role i... […]
- Nutrition: Diet and lifestyle choices you make can ease hypertension on September 17, 2018 at 9:27 am
It’s no surprise that good nutrition positively affects health. In fact, poor diet and physical inactivity are leading causes of chronic illnesses, including Type 2 diabetes and cardiovascular disease ... […]
- Hypertension prediction: Metabolomics model on September 15, 2018 at 2:04 am
Hypertension, also known as high blood pressure, affects about one in three adults worldwide, according to the World Health Organization, and is on the increase. There are two main types. Secondary hy... […]
- Hypertension identified as risk factor for aortic valve disease on September 14, 2018 at 11:01 am
Sustained elevated blood pressure (BP) can increase a patient’s risk for both aortic valve stenosis (AS) and aortic regurgitation (AR), according to an analysis of 5.4 million non-CVD patients in the ... […]
- Resistant Hypertension Now Starts at 130/80 mm Hg on September 14, 2018 at 10:12 am
The American Heart Association (AHA) has released updated recommendations for diagnosis and management of resistant hypertension (RH), which is defined as blood pressure (BP) that remains at >130/80 m... […]
- AHA: Resistant Hypertension Diagnosis, Tx Guidelines Updated on September 14, 2018 at 3:52 am
THURSDAY, Sept. 13, 2018 (HealthDay News) -- A correct diagnosis of resistant hypertension is necessary to avoid overmedicating, according to a scientific statement from the American Heart Association ... […]
- New statement provides detailed overview of how to diagnose, treat resistant hypertension on September 13, 2018 at 11:52 pm
Resistant hypertension affects 12 percent to15 percent of patients treated for high blood pressure according to a new scientific statement from the American Heart Association. The statement, published ... […]
via Bing News